An open label trial of anakinra to prevent respiratory failure in COVID-19

…, E Karakike, M Saridaki, G Loli, A Stefos, D Prasianaki… - Elife, 2021 - elifesciences.org
Background: It was studied if early suPAR-guided anakinra treatment can prevent severe
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR ≥6 ng/ml …

Anakinra to prevent respiratory failure in COVID-19

…, E Karakike, M Saridaki, G Loli, A Stefos, D Prasianaki… - medRxiv, 2020 - medrxiv.org
Introduction The management of pneumonia caused by SARS-CoV-2 should rely on early
recognition of the risk for progression to severe respiratory failure (SRF) and its prevention. …

An open label trial of anakinra to prevent respiratory failure in COVID-19

…, K Eleni, M Saridaki, L Georgia, S Aggelos, P Danai… - eLife, 2021 - search.proquest.com
Background: It was studied if early suPAR-guided anakinra treatment can prevent severe
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR≥ 6 ng/ml …

Anakinra To Prevent Respiratory Failure In COVID-19 (preprint)

…, E Karakike, M Saridaki, G Loli, A Stefos, D Prasianaki… - 2020 - pesquisa.bvsalud.org
Introduction The management of pneumonia caused by SARS-CoV-2 should rely on early
recognition of the risk for progression to severe respiratory failure (SRF) and its prevention. …

[CITATION][C] Anakinra To Prevent Respiratory Failure In COVID-19., medRχvi

…, E Karakike, M Saridaki, G Loli, A Stefos, D Prasianaki… - 2020

[CITATION][C] A RANDOMIZED CLINICAL TRIAL FOR ENHANCED TRAINED IMMUNE RESPONSES THROUGH BACILLUS CALMETTE-GUÉRIN VACCINATION TO …